Chemical warfare agents and other toxins present tremendous dangers for military personnel working in war zones. Dr. Jill Harvilchuck is working to bring new medical countermeasures to market to better protect soldiers and civilians. Jill is Research Leader for the Highly Toxic Materials group at the Battelle Biomedical Research Center (BBRC). Her work focuses primarily on development of countermeasures for chemical warfare agents such as nerve agents. Currently, she is leading a project to study the efficacy of pyridostigmine bromide for use as a pre-treatment for exposure to various chemical agents. Jill’s studies could lead to expanded licensure so it could be approved for use against other chemical agents. She is also leading a project for the use of scopolamine as a potential post-treatment adjunct for nerve agent exposure. Because the compounds she works with are so toxic, most of the work Jill does is conducted under the FDA animal rule, an alternate licensure pathway used in cases where it is not feasible or ethical to conduct efficacy studies on humans.